T2 Biosystms Stock EBITDA
| TTOO Stock | USD 2.72 0.44 13.92% |
T2 Biosystms fundamentals help investors to digest information that contributes to T2 Biosystms' financial success or failures. It also enables traders to predict the movement of TTOO Stock. The fundamental analysis module provides a way to measure T2 Biosystms' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to T2 Biosystms stock.
| Last Reported | Projected for Next Year | ||
| EBITDA | -46.3 M | -48.6 M |
TTOO | EBITDA |
T2 Biosystms Company EBITDA Analysis
T2 Biosystms' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current T2 Biosystms EBITDA | (46.29 M) |
Most of T2 Biosystms' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, T2 Biosystms is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
TTOO EBITDA Driver Correlations
Understanding the fundamental principles of building solid financial models for T2 Biosystms is extremely important. It helps to project a fair market value of TTOO Stock properly, considering its historical fundamentals such as EBITDA. Since T2 Biosystms' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of T2 Biosystms' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of T2 Biosystms' interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
TTOO Ebitda
According to the company disclosure, T2 Biosystms reported earnings before interest,tax, depreciation and amortization of (46.29 Million). This is 105.28% lower than that of the Biotechnology sector and 113.34% lower than that of the Health Care industry. The ebitda for all United States stocks is 101.19% higher than that of the company.
TTOO EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses T2 Biosystms' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of T2 Biosystms could also be used in its relative valuation, which is a method of valuing T2 Biosystms by comparing valuation metrics of similar companies.T2 Biosystms is currently under evaluation in ebitda category among related companies.
T2 Biosystms Institutional Holders
Institutional Holdings refers to the ownership stake in T2 Biosystms that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of T2 Biosystms' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing T2 Biosystms' value.| Shares | Royal Bank Of Canada | 2023-12-31 | 1.3 K | Cwm, Llc Duplicate | 2023-12-31 | 310 | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 120 | Signature Resources Capital Management, Llc | 2023-12-31 | 90.0 | Wells Fargo & Co | 2023-12-31 | 22.0 | Jjj Advisors Inc | 2023-12-31 | 9.0 | U.s. Bancorp | 2023-12-31 | 3.0 | Focused Wealth Strategies, Inc. | 2023-12-31 | 3.0 | Bank Of America Corp | 2023-12-31 | 2.0 | Susquehanna International Group, Llp | 2023-12-31 | 55 K | Vanguard Group Inc | 2023-12-31 | 45.7 K |
TTOO Fundamentals
| Return On Equity | -6.22 | ||||
| Return On Asset | -0.85 | ||||
| Operating Margin | (5.55) % | ||||
| Current Valuation | 49.02 M | ||||
| Shares Outstanding | 8.79 M | ||||
| Shares Owned By Insiders | 4.23 % | ||||
| Shares Owned By Institutions | 49.39 % | ||||
| Number Of Shares Shorted | 374.49 K | ||||
| Price To Earning | (2.04) X | ||||
| Price To Book | 14.50 X | ||||
| Price To Sales | 2.41 X | ||||
| Revenue | 7.19 M | ||||
| Gross Profit | (24.77 M) | ||||
| EBITDA | (46.29 M) | ||||
| Net Income | (50.08 M) | ||||
| Cash And Equivalents | 13.21 M | ||||
| Cash Per Share | 1.87 X | ||||
| Total Debt | 49.5 M | ||||
| Debt To Equity | 6.64 % | ||||
| Current Ratio | 1.87 X | ||||
| Book Value Per Share | (6.91) X | ||||
| Cash Flow From Operations | (48.2 M) | ||||
| Short Ratio | 1.59 X | ||||
| Earnings Per Share | (19.19) X | ||||
| Target Price | 12.0 | ||||
| Number Of Employees | 113 | ||||
| Beta | 0.099 | ||||
| Market Capitalization | 24.27 M | ||||
| Total Asset | 34.8 M | ||||
| Retained Earnings | (584.3 M) | ||||
| Working Capital | (30.96 M) | ||||
| Current Asset | 77.78 M | ||||
| Current Liabilities | 18.54 M | ||||
| Net Asset | 34.8 M |
About T2 Biosystms Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze T2 Biosystms's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of T2 Biosystms using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of T2 Biosystms based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards T2 Biosystms in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, T2 Biosystms' short interest history, or implied volatility extrapolated from T2 Biosystms options trading.
Currently Active Assets on Macroaxis
When determining whether T2 Biosystms offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of T2 Biosystms' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of T2 Biosystms Stock. Outlined below are crucial reports that will aid in making a well-informed decision on T2 Biosystms Stock:Check out T2 Biosystms Piotroski F Score and T2 Biosystms Altman Z Score analysis. To learn how to invest in TTOO Stock, please use our How to Invest in T2 Biosystms guide.You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Complementary Tools for TTOO Stock analysis
When running T2 Biosystms' price analysis, check to measure T2 Biosystms' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy T2 Biosystms is operating at the current time. Most of T2 Biosystms' value examination focuses on studying past and present price action to predict the probability of T2 Biosystms' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move T2 Biosystms' price. Additionally, you may evaluate how the addition of T2 Biosystms to your portfolios can decrease your overall portfolio volatility.
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |
Is T2 Biosystms' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of T2 Biosystms. If investors know TTOO will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about T2 Biosystms listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (19.19) | Revenue Per Share 2.756 | Quarterly Revenue Growth (0.69) | Return On Assets (0.85) | Return On Equity (6.22) |
The market value of T2 Biosystms is measured differently than its book value, which is the value of TTOO that is recorded on the company's balance sheet. Investors also form their own opinion of T2 Biosystms' value that differs from its market value or its book value, called intrinsic value, which is T2 Biosystms' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because T2 Biosystms' market value can be influenced by many factors that don't directly affect T2 Biosystms' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between T2 Biosystms' value and its price as these two are different measures arrived at by different means. Investors typically determine if T2 Biosystms is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, T2 Biosystms' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.